Immune responses to AAV vectors: Overcoming barriers to successful gene therapy

Blood

Volumn 122, Issue 1, 2013, Pages 23-36

  Mingozzi, Federico ^a,d,e   High, Katherine A ^a,b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SORBONNE UNIVERSITÉ   (France)

^e GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; B LYMPHOCYTE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); GAUCHER DISEASE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMOCHROMATOSIS; HEMOPHILIA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; PORPHYRIA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THERAPY; TRANSGENE; VIRAL TROPISM; VIRION; VIRUS CAPSID; WILD TYPE; ADENO ASSOCIATED VIRUS; BLOOD; GENE VECTOR; GENETIC DISORDER; GENETICS; IMMUNOLOGY; METHODOLOGY;

ANTIBODIES, VIRAL; DEPENDOVIRUS; GENETIC DISEASES, INBORN; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84883268937     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-306647     Document Type: Review

References (146)

1. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J M ed. 2009; 360(5):447-458.
2. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326(5954):818-823.
3. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature. 2010;467(7313):318-322.
4. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vectormediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
5. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008; 358(21):2231-2239. (Pubitemid 351724452)
6. Maguire AM, High KA, Auricchio A, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 doseescalation trial. Lancet. 2009;374(9701): 1597-1605.
7. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008; 358(21):2240-2248. (Pubitemid 351724453)
8. Pollack A. European agency backs approval of a gene therapy. New York Times. July 20, 2012:B1.
9. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A. 2002;99(16):10405-10410.
10. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5): 341-355.
11. High KA. The gene therapy journey for hemophilia: are we there yet? Blood. 2012; 120(23):4482-4487.
12. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9-24.
13. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007;369(9579):2097-2105. (Pubitemid 46935946)
14. Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med. 2012;4(165):165ra163.
15. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response [published correction appears in Nat Med. 2006;12(5):592]. Nat Med. 2006;12(3):342-347. (Pubitemid 43355084)
16. Carpentier AC, Frisch F, Labb́e SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635-1644.
17. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA. 2009;106(38): 16363-16368.
18. Manno CS, Chew AJ, Hutchison S, et al. AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963-2972. (Pubitemid 36857981)
19. Jaski BE, Jessup ML, Mancini DM, et al; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15(3): 171-181.
20. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci USA. 1966;55(6):1467-1474.
21. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704-712.
22. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol. 1998;72(4): 3241-3247. (Pubitemid 28175569)
23. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93(24):14082-14087. (Pubitemid 26424249)
24. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70(11):8098-8108. (Pubitemid 26339120)
25. Efficient and persistent gene transfer of AAVCFTR in maxillary sinus. Lancet. 1998; 351(9117):1702-1703. (Pubitemid 28254535)
26. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24(3):257-261. (Pubitemid 30132193)
27. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-158. (Pubitemid 37272241)
28. Marshall E. Gene therapy on trial. Science. 2000;288(5468):951-957. (Pubitemid 30324217)
29. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost. 2007;5(1):16-24. (Pubitemid 44921062)
30. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009; 119(8):2388-2398.
31. Suzuki M, Bertin TK, Rogers GL, et al. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther. 2013;21(4):796-805.
32. Jayandharan GR, Aslanidi G, Martino AT, et al. Activation of the NF-kappaB pathway by adenoassociated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci USA. 2011;108(9): 3743-3748.
33. Sudres M, Ciré S, Vasseur V, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther. 2012;20(8):1571-1581.
34. Martino AT, Suzuki M, Markusic DM, et al. The genome of self-complementary adenoassociated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011;117(24):6459-6468.
35. Hösel M, Broxtermann M, Janicki H, et al. Tolllike receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012;55(1):287-297.
36. High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol. 2011;807: 429-457.
37. Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood. 2006;107(5):1810-1817. (Pubitemid 43289358)
38. Murphy SL, Li H, Zhou S, Schlachterman A, High KA. Prolonged susceptibility to antibodymediated neutralization for adeno-associated vectors targeted to the liver [published correction appears in Mol Ther. 2008;16(3):633]. Mol Ther. 2008;16(1):138-145.
39. Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 2006;108(10):3321-3328.
40. Mingozzi F, Chen Y, Edmonson SC, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 2013;20 (4):417-424.
41. Cottard V, Valvason C, Falgarone G, Lutomski D, Boissier MC, Bessis N. Immune response against gene therapy vectors: influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J Clin Immunol. 2004;24(2):162-169. (Pubitemid 38457230)
42. Arruda VR, Stedman HH, Haurigot V, et al. Peripheral transvenular delivery of adenoassociated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood. 2010; 115(23):4678-4688.
43. Rodino-Klapac LR, Montgomery CL, Bremer WG, et al. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther. 2010;18(1):109-117.
44. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012; 23(4):382-389.
45. Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med. 2010;2(21):21ra16.
46. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012; 4(120):120ra15.
47. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA. 2008;105(39):15112-15117.
48. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28(12):2303-2304.
49. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980-1983.
50. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19(5): 463-474. (Pubitemid 351748791)
51. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-1172.
52. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008;7(5):400-408.
53. Calcedo R, Morizono H, Wang L, et al. Adenoassociated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. 2011;18(9):1586-1588.
54. Erles K, Sebökov́a P, Schlehofer Jr. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59(3):406-411. (Pubitemid 29468085)
55. Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adenoassociated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012;19(3):288-294.
56. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99(18):11854-11859. (Pubitemid 34994488)
57. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82(12): 5887-5911. (Pubitemid 351822263)
58. Asokan A, Conway JC, Phillips JL, et al. Reengineering a receptor footprint of adenoassociated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol. 2010; 28(1):79-82.
59. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol. 2006;24(2):198-204. (Pubitemid 43221704)
60. Arruda VR, Xiao W. It's all about the clothing: capsid domination in the adeno-associated viral vector world. J Thromb Haemost. 2007;5(1): 12-15. (Pubitemid 44921061)
61. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. J Virol. 1999;73(2):1309-1319. (Pubitemid 29036786)
62. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381-390.
63. Murphy SL, Li H, Mingozzi F, et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J Med Virol. 2009;81(1):65-74.
64. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10): 2077-2086.
65. Miao CH. Advances in overcoming immune responses following hemophilia gene therapy. J Genet Syndr Gene Ther. 2011;S1:007.
66. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264-283.
67. Mingozzi F, Maus MV, Hui DJ, et al. CD8(1) Tcell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-422. (Pubitemid 46559826)
68. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV. Directed evolution of adenoassociated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther. 2012;20(2):329-338.
69. Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 2012; 19(6):694-700.
70. Stone D, Koerber JT, Mingozzi F, Podsakoff GM, High KA, Schaffer DV. Directed evolution of adeno-associated virus variants that evade human neutralizing antibodies [abstract]. Mol Ther. 2010;18(suppl 1):S3. Abstract 8.
71. Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011;19(11):2084-2091.
72. Mimuro J, Mizukami H, Hishikawa S, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther. 2013;21(2):318-323.
73. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liverdirected gene therapy. Blood. 2002;99(8): 2670-2676. (Pubitemid 34525351)
74. Li C, Hirsch M, Asokan A, et al. Adenoassociated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vectortransduced cells coexpressing the AAV2 capsid in vivo. J Virol. 2007;81(14):7540-7547. (Pubitemid 47047840)
75. Li H, Murphy SL, Giles-Davis W, et al. Preexisting AAV capsid-specific CD81 T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther. 2007;15(4):792-800. (Pubitemid 46432000)
76. Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther. 2007;18(3): 185-194. (Pubitemid 46626458)
77. Li H, Tuyishime S, Wu TL, et al. Adenoassociated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD81 T cells in mice. Mol Ther. 2011;19(3):536-546.
78. Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD81 T cells. Blood. 2013; 121(12):2224-2233.
79. Gao G, Wang Q, Calcedo R, et al. Adenoassociated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther. 2009;20(9):930-942.
80. Li H, Lasaro MO, Jia B, et al. Capsid-specific T-cell responses to natural infections with adenoassociated viruses in humans differ from those of nonhuman primates. Mol Ther. 2011;19(11): 2021-2030.
81. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA. 2006;103(20):7765-7770.
82. Report on immune responses to adenoassociated virus (AAV) vectors. Office of Biotechnology Activities, NIH Recombinant DNA Advisory Committee Meeting, June 19, 2007. http://oba.od.nih.gov/rdna-rac/rac-meetings.html. Accessed May 20, 2012.
83. Hui DJ, Mingozzi F, Basner-Tschakarjan E, et al. Characterization of AAV capsid responses in humans using normal donor splenocytes. Mol Ther. 2007;15:S99.
84. Chadeuf G, Ciron C, Moullier P, Salvetti A. Evidence for encapsidation of prokaryotic sequences during recombinant adenoassociated virus production and their in vivo persistence after vector delivery. Mol Ther. 2005; 12(4):744-753. (Pubitemid 41350156)
85. Hui DJ, Basner-Tschakarjan E, Chen Y, et al. Characterization of AAV T cells epitopes presented by splenocytes from normal human donors [abstract]. Mol Ther. 2012;20(suppl 1): S215. Abstract 557.
86. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther. 2009;17(1): 144-152.
87. Li C, Goudy K, Hirsch M, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA. 2009; 106(26):10770-10774.
88. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med. 2006;12(8):967-971. (Pubitemid 44175151)
89. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest. 2000;105(11):1573-1587. (Pubitemid 30390308)
90. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol. 2002;76(5): 2043-2053. (Pubitemid 34150672)
91. Finn JD, Hui D, Downey HD, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther. 2010;18(1):135-142.
92. Monahan PE, Lothrop CD, Sun J, et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther. 2010; 18(11):1907-1916.
93. Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adenoassociated viral vectors. Gene Ther. 2009;16(1): 60-69.
94. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA. 2008;105(22):7827-7832. (Pubitemid 351872723)
95. Pien GC, Basner-Tschakarjan E, Hui DJ, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest. 2009;119(6):1688-1695.
96. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003;10(26):2112-2118. (Pubitemid 37536760)
97. Nathwani AC, Gray JT, Ng CY, et al. Selfcomplementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107(7):2653-2661.
98. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adenoassociated viral vector expressing a1-antitrypsin: interim results. Hum Gene Ther. 2011;22(10): 1239-1247.
99. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010;363(15): 1429-1437.
100. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010; 68(5):629-638.
101. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alphasarcoglycan and associated proteins. Ann Neurol. 2009;66(3):290-297.
102. Herson S, Hentati F, Rigolet A, et al. A phase I trial of adeno-associated virus serotype 1-g-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain. 2012; 135(pt 2):483-492.
103. Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adenoassociated virus vector-mediated gene therapy. Blood. 2009;113(3):538-545.
104. Hudig D, Haverty T, Fulcher C, Redelman D, Mendelsohn J. Inhibition of human natural cytotoxicity by macromolecular antiproteases. J Immunol. 1981;126(4):1569-1574. (Pubitemid 11149266)
105. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-305. (Pubitemid 34303674)
106. Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAVmediated gene transfer. Blood. 2012;119(13): 3038-3041.
107. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20): 1662-1669.
108. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med. 2006;8(5): 577-588. (Pubitemid 43827251)
109. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671-1675.
110. Cantore A, Nair N, Della Valle P, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood. 2012;120(23):4517-4520.
111. Finn JD, Nichols TC, Svoronos N, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood. 2012;120(23): 4521-4523.
112. Matsushita T, Elliger S, Elliger C, et al. Adenoassociated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998; 5(7):938-945. (Pubitemid 28371911)
113. Kotin RM. Large-scale recombinant adenoassociated virus production. Hum Mol Genet. 2011;20(R1):R2-R6.
114. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 1995;6(10):1329-1341.
115. Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol. 2010;37(8):1570-1578.
116. Zhou J, Yang X, Wright JF, High KA, Couto L, Qu G. PEG-modulated column chromatography for purification of recombinant adeno-associated virus serotype 9. J Virol Methods. 2011;173(1): 99-107.
117. Ayuso E, Mingozzi F, Montane J, et al. High AAV vector purity results in serotype- and tissueindependent enhancement of transduction efficiency. Gene Ther. 2010;17(4):503-510.
118. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. 2008;15(11):840-848. (Pubitemid 351712617)
119. Mingozzi F, Anguela XM, Pavani G, et al. A novel strategy to circumvent pre-existing humoral immunity to AAV. In: Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. In press: 2013.
120. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ, Samulski RJ. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol. 2010;84(17):8888-8902.
121. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111(9):1347-1356. (Pubitemid 36554705)
122. Dobrzynski E, Mingozzi F, Liu YL, et al. Induction of antigen-specific CD41 T-cell anergy and deletion by in vivo viral gene transfer. Blood. 2004;104(4):969-977. (Pubitemid 39038015)
123. Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther. 2005;12(5):876-884. (Pubitemid 41614483)
124. Ziegler RJ, Lonning SM, Armentano D, et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 2004;9(2):231-240. (Pubitemid 38256549)
125. Martino AT, Nayak S, Hoffman BE, et al. Tolerance induction to cytoplasmic betagalactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. PLoS ONE. 2009;4(8):e6376.
126. Cao O, Dobrzynski E, Wang L, et al. Induction and role of regulatory CD41CD251 T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 2007; 110(4):1132-1140. (Pubitemid 47281408)
127. Markusic DM, Herzog RW. Hepatic gene transfer of factor IX reverses inhibitors and protects from anaphylaxis in a murine hemophilia B model [abstract]. Blood. 2011; 118(21). Abstract 669.
128. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAVmediated gene transfer to liver. Blood. 2007; 110(7):2334-2341. (Pubitemid 47523153)
129. Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116(26):5842-5848.
130. Wu T, Töpfer K, Lin SW, et al. Selfcomplementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther. 2012;20(3):572-579.
131. Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004; 103(9):3300-3302. (Pubitemid 38525655)
132. Haurigot V, Mingozzi F, Buchlis G, et al. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther. 2010;18(7):1318-1329.
133. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001; 4(3):192-200. (Pubitemid 32851282)
134. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther. 2007;15(6):1160-1166. (Pubitemid 46813619)
135. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther. 2006;17(12): 1177-1186. (Pubitemid 44975135)
136. Cordier L, Gao GP, Hack AA, et al. Musclespecific promoters may be necessary for adenoassociated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther. 2001;12(2):205-215. (Pubitemid 32095458)
137. Koo T, Okada T, Athanasopoulos T, Foster H, Takeda S, Dickson G. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med. 2011;13(9):497-506.
138. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med. 2006;12(5):585-591.
139. Boisgérault F, Gross DA, Ferrand M, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther. 2013;24(4): 393-405.
140. Wang Z, Storb R, Halbert CL, et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther. 2012;20(8):1501-1507.
141. Su LT, Gopal K, Wang Z, et al. Uniform scaleindependent gene transfer to striated muscle after transvenular extravasation of vector. Circulation. 2005;112(12):1780-1788. (Pubitemid 41368154)
142. Toromanoff A, Adjali O, Larcher T, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther. 2010;18(1):151-160.
143. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475(7355): 217-221.
144. Russell DW. AAV vectors, insertional mutagenesis, and cancer. Mol Ther. 2007; 15(10):1740-1743. (Pubitemid 47434179)
145. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477. (Pubitemid 47196106)
146. Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood. 2011;117(12): 3311-3319.